无BRAFV600E的朗格汉斯细胞组织细胞增生症中突变的细胞分布及其与疾病风险的关联 - Suppr

Suppr

超能文献

Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E.

作者信息

Milne Paul, Abhyankar Harshal, Scull Brooks, Singh Preeti, Chakraborty Rikhia, Allen Carl E, Collin Matthew

机构信息

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; and.

Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX; and.

出版信息

Blood Adv. 2022 Aug 23;6(16):4901-4904. doi: 10.1182/bloodadvances.2022007519.

DOI:10.1182/bloodadvances.2022007519

PMID:35816634

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631653/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb47/9631653/28ab6499fde5/advancesADV2022007519f1.jpg

相似文献

Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E.无BRAFV600E的朗格汉斯细胞组织细胞增生症中突变的细胞分布及其与疾病风险的关联

Blood Adv. 2022 Aug 23;6(16):4901-4904. doi: 10.1182/bloodadvances.2022007519.

BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.朗格汉斯细胞组织细胞增多症中的BRAFV600E和MAP2K1突变主要发生在儿童中。

Hematol Oncol. 2017 Dec;35(4):845-851. doi: 10.1002/hon.2344. Epub 2016 Sep 6.

Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.日本19例朗格汉斯细胞组织细胞增多症中BRAFV600E突变的分析。

Hematol Oncol. 2017 Sep;35(3):329-334. doi: 10.1002/hon.2293. Epub 2016 Apr 4.

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.朗格汉斯细胞组织细胞增生症中，BRAFV600E 突变蛋白在具有不同成熟度的细胞中表达。

Blood. 2012 Sep 20;120(12):e28-34. doi: 10.1182/blood-2012-06-429597. Epub 2012 Aug 2.

Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis.BRAFV600E 在多系统朗格汉斯细胞组织细胞增生症中细胞分布的谱系转换。

Blood Adv. 2023 May 23;7(10):2171-2176. doi: 10.1182/bloodadvances.2021006732.

BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.BRAFV600E 突变在成人朗格汉斯细胞组织细胞增生症患者的皮肤病变中的存在。

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1205-11. doi: 10.1111/jdv.12792. Epub 2014 Oct 28.

Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.儿童朗格汉斯细胞组织细胞增生症的临床基因组关联：一项国际队列研究。

Blood Adv. 2023 Feb 28;7(4):664-679. doi: 10.1182/bloodadvances.2022007947.

Langerhans cell histiocytosis: current advances in molecular pathogenesis.朗格汉斯细胞组织细胞增生症：分子发病机制的最新进展。

Front Immunol. 2023 Oct 26;14:1275085. doi: 10.3389/fimmu.2023.1275085. eCollection 2023.

Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.与淋巴瘤相关的朗格汉斯细胞组织细胞增多症：一种与BRAF或MAP2K1突变无关的偶然发现。

Mod Pathol. 2017 May;30(5):734-744. doi: 10.1038/modpathol.2016.235. Epub 2017 Jan 13.

Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.儿童朗格汉斯细胞组织细胞增生症中的体细胞 ARAF 突变：临床病理、遗传和功能分析。

Clin Exp Med. 2023 Dec;23(8):5269-5279. doi: 10.1007/s10238-023-01134-w. Epub 2023 Aug 12.

引用本文的文献

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms.髓系和淋巴系细胞中的驱动突变表明多种组织细胞肿瘤起源于多能祖细胞。

Blood Neoplasia. 2025 Jan 27;2(2):100074. doi: 10.1016/j.bneo.2025.100074. eCollection 2025 May.

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.荷兰和比利时组织细胞肿瘤患者靶向治疗的真实世界经验。

Blood Neoplasia. 2024 Jun 10;1(3):100023. doi: 10.1016/j.bneo.2024.100023. eCollection 2024 Sep.

Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.朗格汉斯细胞组织细胞增生症：NACHO 对进展、混乱和理性治疗之路的机会的更新。

Cancer. 2024 Jul 15;130(14):2416-2439. doi: 10.1002/cncr.35301. Epub 2024 Apr 30.

Langerhans cell histiocytosis: current advances in molecular pathogenesis.朗格汉斯细胞组织细胞增生症：分子发病机制的最新进展。

Front Immunol. 2023 Oct 26;14:1275085. doi: 10.3389/fimmu.2023.1275085. eCollection 2023.

Langerhans Cell Histiocytosis with Good Response to Low-Dose Imatinib: Case Report and Literature Review.对低剂量伊马替尼反应良好的朗格汉斯细胞组织细胞增多症：病例报告及文献综述

Case Rep Oncol. 2023 Jul 12;16(1):511-518. doi: 10.1159/000531230. eCollection 2023 Jan-Dec.

Blood Adv. 2023 Feb 28;7(4):664-679. doi: 10.1182/bloodadvances.2022007947.

Genomic profiling for clinical decision making in lymphoid neoplasms.淋巴肿瘤临床决策的基因组分析。

Blood. 2022 Nov 24;140(21):2193-2227. doi: 10.1182/blood.2022015854.

本文引用的文献

Histiocytic disorders.组织细胞增生症。

Nat Rev Dis Primers. 2021 Oct 7;7(1):73. doi: 10.1038/s41572-021-00307-9.

Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis.在诊断时，游离 DNA 中的突变而非病变组织中的突变，是朗格汉斯细胞组织细胞增生症患儿的一个独立预后因素。

Mol Cancer Ther. 2021 Jul;20(7):1316-1323. doi: 10.1158/1535-7163.MCT-20-1075. Epub 2021 Apr 20.

Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis.骨髓源性髓系前体细胞作为高风险和低危朗格汉斯细胞组织细胞增生症的驱动突变携带者。

Blood. 2020 Nov 5;136(19):2188-2199. doi: 10.1182/blood.2020005209.

Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans.差异的 IRF8 转录因子需求定义了人类树突状细胞发育的两条途径。

Immunity. 2020 Aug 18;53(2):353-370.e8. doi: 10.1016/j.immuni.2020.07.003. Epub 2020 Jul 30.

MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.MAP 激酶驱动的造血肿瘤：分子时代的十年进展。

Cold Spring Harb Perspect Med. 2021 May 3;11(5):a034892. doi: 10.1101/cshperspect.a034892.

Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells.循环 CD1c+髓系树突状细胞可能是 LCH 病变 CD1a+CD207+细胞的前体细胞。

Blood Adv. 2020 Jan 14;4(1):87-99. doi: 10.1182/bloodadvances.2019000488.

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.在组织细胞肿瘤中 CSF1R 和其他受体酪氨酸激酶的激活突变。

Nat Med. 2019 Dec;25(12):1839-1842. doi: 10.1038/s41591-019-0653-6. Epub 2019 Nov 25.

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.维莫非尼治疗儿童难治性多系统朗格汉斯细胞组织细胞增生症：一项国际观察性研究。

J Clin Oncol. 2019 Nov 1;37(31):2857-2865. doi: 10.1200/JCO.19.00456. Epub 2019 Sep 12.

Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.朗格汉斯细胞组织细胞增生症患者外周血 BRAFV600E 水平的纵向评估。

Pediatr Res. 2019 May;85(6):856-864. doi: 10.1038/s41390-018-0238-y. Epub 2018 Nov 24.

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.临床神经退行性朗格汉斯细胞组织细胞增生症的发病率和危险因素：一项纵向队列研究。

Br J Haematol. 2018 Nov;183(4):608-617. doi: 10.1111/bjh.15577. Epub 2018 Nov 12.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验